New Cervical Cancer Tests and How They Relate To Anti-Aging Medicine
s of human cellular DNA altered by precancerous changes. This early study online in Cancer Prevention Research on November 8, the investigators say their genetic markers test showed a accuracy rate of 90.9 percent in identifying so-called CIN2 lesions which are the high grade cervical changes that have at least 1/10 chance of becoming a malignancy if untreated. Additionally, they demonstrated that the DNA for all three human genes and one viral gene could be successfully extracted from urine, and they could identify such lesions with 75 percent sensitivity. Antiaging medicine has shown that oxidation, methylation, glycosilation, and chelation of our cells, our DNA, and our tissues ages us. Aging processes can also lead to cancer. Two tests based on markers of DNA chemical changes called methylation, released in Europe last summer, and are an advancement in the science of cervical cancer detection but do require Pap smear swabs of cervical tissue, and show 64 percent sensitivity in identifying similar lesions, and of course then require further testing, which can be both uncomfortable and expensive to really detect any new disease. The emphasis in cervical cancer detection strategies has been how to prevent disease with more targeted testing, and fewer tests.This new test could help establish who to watch and not do further testing on. Their new test looks at three genes associated with cervical cancer or abnormal-looking cells known to become cancerous: FKBP6, INTS1 and ZNF516. As abnormalities progress, these genes were more likely to have a chemical methyl group attached to their DNA in certain spots. As an aside, the anti-aging medication physicians would venture that preventing methylation, and reversing methylation, would ultimately attack the problem at the root. Most physicians have been focused on disease cure rather than prevention as we have lacked effective testing to show us how to track the results of therapy.
Using methylation as a value to diagnose cervical malignancy, the three genes together showed a 90 percent sensitivity, meaning that their presence was able to predict a true positive cancer sample this percentage of the time. This new test uses those three genes and added one HPV viral gene HPV16-L1 to test for in urine The gene the virus, HPV16-L1, which also becomes methylated in human cells as cancer develops. So there it is, even the HPV virus gene ages and becomes more deadly!
The research was funded by National Cancer Institute grants (U01 CA084986, K01 CA164092 and U01 CA084986).